Myoinositol
Phase 3Small molecule
Myoinositol is one of 68 small molecule programs targeting Ovarian Reserve. It is currently in Phase 3.
4
Indications
11
Total Trials
3
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Myoinositol
SSohag University
Phase 3
Acipimox
Boehringer IngelheimPhase 2
Zyloprim
Jazz PharmaceuticalsPreclinical
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Aricept
EisaiPreclinical
TY-9591
TTYK Medicines, Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome3 trials
Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome
Completed·—·N/A·NCT01791647·40 enrolled
Metformin2 trials
Polycystic Ovarian Syndrome (PCOS)1 trial
Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
Completed·—·N/A·NCT07058675·156 enrolled
Growth1 trial
Ovarian Reserve1 trial
of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
Not yet recruiting·—·Phase 3·NCT06405204·200 enrolled
3 more indications
Outcome1 trial
Polycystic Ovarian Syndrome1 trial
Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
Not yet recruiting·—·Phase 3·NCT06405243·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Myoinositol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSohag University